Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia

Drug Development Research

Volumn 16, Issue 1, 1989, Pages 79-83

  Munetz, Mark R ^a,b   Schulz, S Charles ^a,c   Bellin, Marvin ^a   Harty, Irma ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

carbazole compound; extrapyramidal side effects; rimcazole (BW234U) schizophrenia maintenance

Indexed keywords

HALOPERIDOL; RIMCAZOLE;

CLINICAL ARTICLE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA;

EID: 0024324034     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.430160109     Document Type: Article

References (8)

1. An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients
2. Dopamine receptor binding predicts clinical and pharmacological potencies of anti‐schizophrenic drugs
3. BW234U: A nondopamine receptor‐blocking antipsychotic drug without extrapyramidal side effects?
4. The first clinical study of BW‐234U in schizophrenia
5. BW234U (cis‐9‐[3‐(3,5‐dimethyl‐1‐piperazinyl]carbazole dihydrochloride)): A novel antipsychotic agent
6. Psychotropic actions of BW234U in the treatment of inpatient schizophrenics: A dose‐range study
7. Apomorphine‐induced aggression in the rat
8. Open label evaluation of novel antipsychotic compound BW234U in chronic schizophrenics